Retatrutide, by Soma Corp., is attracting significant attention as a novel therapy for weight regulation. This innovative medication merges the mechanism of a GLP-1 receptor agonist and a GIP receptor activator , aiming to effectively promote reduced body fat but also address related metabolic fa